Based on targeting COX2 and modulating the Keap1 - Nrf2 and ER stress - related pathways, we preliminarily explored the underlying mechanism of EPT in alleviating early NAFLD progression. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatotic liver disease.